High levels of lipoprotein(a) - assessment and treatment.

Tone SvilaasTor Ole KlemsdalMartin Prøven BogsrudAsgeir GræsdalElisabeth Kleivhaug VesterbekkmoEmil Andreas AsprustenGisle LangsletKjetil Retterstøl

Published in: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke (2022)

Approximately 5 % of the population have highly elevated levels of lipoprotein(a) (Lp(a)), which is a genetically determined risk factor for cardiovascular disease. Measuring lipoprotein(a) can improve cardiovascular risk stratification and have consequences for preventive measures. Treatment is targeted at reducing modifiable cardiovascular risk factors, but Lp(a)-lowering drugs are being trialled. This article reviews the management of lipoprotein(a) in clinical practice.

Keyphrases

cardiovascular risk factors
cardiovascular disease
clinical practice
metabolic syndrome
type diabetes
randomized controlled trial
combination therapy
cancer therapy
replacement therapy
smoking cessation